Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines

American Journal of Cardiology

Volumn 101, Issue 12 SUPPL., 2008, Pages

  Davidson, Michael H ^a,b   Corson, Marshall A ^c   Alberts, Mark J ^d   Anderson, Jeffrey L ^e   Gorelick, Philip B ^f   Jones, Peter H ^g   Lerman, Amir ^h   McConnell, Joseph P ⁱ   Weintraub, Howard S ^j  

^a UNIVERSITY OF CHICAGO   (United States)

^b RADIANT RESEARCH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e LDS HOSPITAL   (United States)

^f UNIVERSITY OF ILLINOIS   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h Mayo Clinic   (United States)

ⁱ Departments of Cardiovascular Diseases   (United States)

^j NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2;

ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HUMAN; INFLAMMATION; LIFESTYLE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CONSENSUS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 51749093324     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.04.019     Document Type: Article

References (37)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421 II-30-II-31
2. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J., National Heart, and Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
3. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Myers H.Y., Myers G.L., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
4. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 113 (2006) 2363-2372
5. 2 and cardiovascular disease: a systematic review. Mayo Clin Proc 82 (2007) 159-165
6. 2, high-sensitivity C-reactive protein, and risk for incident heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
7. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany (MONICA-Augsburg). Circulation 110 (2004) 1903-1908
8. 2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 152 (2006) 997-1003
9. Wolf P.A., D'Agostino R.B., Belanger A.J., and Kannel W.B. Probability of stroke: a risk profile from the Framingham Study. Stroke 22 (1991) 312-318
10. Goldstein L.B., Adams R., Alberts M.J., Appel L.J., Brass L.M., Bushnell C.D., Culebras A., DeGraba T.J., Gorelick P.B., Guyton J.R., et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 37 (2006) 1583-1633
11. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Bevers G., Caulfield M., Collins R., Kjeldsen S.E., Dristinsson A., McInnes G.T., et al., ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361 (2003) 1149-1158
12. Coull B.M. Statin therapy after acute ischemic stroke in the heart protection study: is the role in recurrent stroke prevention now defined?. Stroke 35 (2004) 2233-2234
13. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A.W., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., and Fuller J.H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 684-696
14. 2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 27 (2007) 1411-1416
15. 2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 7 (2007) 511-517
16. 2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 101 suppl 12A (2008) 23F-33F
17. Moldoveanu E., Tanaseanu C., Tanaseanu S., Kosaka T., Manea G., Marta D.S., and Popescu L.M. Plasma markers of endothelial dysfunction in type 2 diabetics. Eur J Intern Med 17 (2006) 38-42
18. Winkler K., Abletshauser C., Friedrich I., Hoffmann M.M., Wieland H., and März W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 1153-1159
19. 2, and hypertriglyceridemia predict risk for recurrent coronary events in diabetic post-infarction patients. Diabetes 56 (2007) 1429-1435
20. 2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26 (2005) 137-144
21. 2. Presented at the American Heart Association Epidemiology and Vascular Biology Annual Meeting; Phoenix, Arizona, March 2-5, 2006. Abstract P107.
22. 2 predicts 5-year mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 53 (2007) 1440-1447
23. Mosca L., Appel L.J., Benjamin E.J., Berra K., Chandra-Stobos N., Fabunmi R.P., Grady D., Haan C.K., Hayes S.N., Judelson D.R., et al., American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109 (2004) 672-693
24. 2 in chronic kidney disease: results from the RRI-CKD Study. Presented at the American College of Cardiology 55th Annual Scientific Sessions Meeting; March 11-14, 2006; Atlanta, Georgia. Abstract 854-7.
25. 2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress (KAROLA). Arterioscler Thromb Vasc Biol 26 (2006) 1586-1593
26. Ridker P.M., Cannon C.P., Morrow D., Rifai N., McCabe C.H., Pfeffer M.A., Braunwald E., and PROVE IT-TIMI 22 Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
27. 2: review and recommendation of a clinical cut point for adults. Prev Cardiol 9 (2006) 138-143
28. 2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 26 (2006) 2517-2522
29. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.-C., Gotto A.M., Greten H., Kastelein J.J.P., Shepherd J., Wenger N.K., and Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
30. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
31. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.C., Davis B.R., Braunwald E., and Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
32. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
33. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
34. Sisson S.D., Rice T.N., and Hughes M.T. Physician knowledge of national cholesterol guidelines before and after an interactive curriculum. Am J Cardiol 99 (2007) 1234-1235
35. 2, and outcome after ischemic stroke. Arch Intern Med 166 (2006) 2073-2080
36. Boden W.E., O'Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J., Knudtson M., Dada M., Casperson P., Harris C.L., et al., COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007) 1503-1516
37. Lewington S., Whitlock G., Clarke R., Sherliker P., Emberson J., Halsey J., Qizilbash N., Peto R., and Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies of 55,000 vascular deaths. Lancet 370 (2007) 1829-1839